These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2655343)

  • 21. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge.
    Mader D; Huang Y; Wang C; Fraser R; Issekutz AC; Stadnyk AW; Anderson R
    Vaccine; 2000 Jan; 18(11-12):1110-7. PubMed ID: 10590333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice.
    Boelen A; Andeweg A; Kwakkel J; Lokhorst W; Bestebroer T; Dormans J; Kimman T
    Vaccine; 2000 Nov; 19(7-8):982-91. PubMed ID: 11115725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine.
    Kakuk TJ; Soike K; Brideau RJ; Zaya RM; Cole SL; Zhang JY; Roberts ED; Wells PA; Wathen MW
    J Infect Dis; 1993 Mar; 167(3):553-61. PubMed ID: 8440926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
    Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
    Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice.
    Power UF; Huss T; Michaud V; Plotnicky-Gilquin H; Bonnefoy JY; Nguyen TN
    J Virol; 2001 Dec; 75(24):12421-30. PubMed ID: 11711632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model.
    Ponnuraj EM; Springer J; Hayward AR; Wilson H; Simoes EA
    J Infect Dis; 2003 Apr; 187(8):1257-63. PubMed ID: 12696005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of cell-mediated cytotoxic activity in the respiratory tract after experimental infection with respiratory syncytial virus.
    Kumagai T; Wong DT; Ogra PL
    Clin Exp Immunol; 1985 Aug; 61(2):351-9. PubMed ID: 3899431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV.
    Johnson TR; Varga SM; Braciale TJ; Graham BS
    J Virol; 2004 Aug; 78(16):8753-60. PubMed ID: 15280483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus.
    Kanesaki T; Murphy BR; Collins PL; Ogra PL
    J Virol; 1991 Feb; 65(2):657-63. PubMed ID: 1987374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection.
    De Swart RL; Kuiken T; Timmerman HH; van Amerongen G; Van Den Hoogen BG; Vos HW; Neijens HJ; Andeweg AC; Osterhaus AD
    J Virol; 2002 Nov; 76(22):11561-9. PubMed ID: 12388717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines.
    Ottolini MG; Porter DD; Hemming VG; Prince GA
    Viral Immunol; 2000; 13(2):231-6. PubMed ID: 10893002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat.
    Gruber WC; Wilson SZ; Throop BJ; Wyde PR
    Pediatr Res; 1987 Mar; 21(3):270-4. PubMed ID: 3550674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Innate and adaptive cellular phenotypes contributing to pulmonary disease in mice after respiratory syncytial virus immunization and infection.
    Lee YT; Kim KH; Hwang HS; Lee Y; Kwon YM; Ko EJ; Jung YJ; Lee YN; Kim MC; Kang SM
    Virology; 2015 Nov; 485():36-46. PubMed ID: 26196232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.
    O'Konek JJ; Makidon PE; Landers JJ; Cao Z; Malinczak CA; Pannu J; Sun J; Bitko V; Ciotti S; Hamouda T; Wojcinski ZW; Lukacs NW; Fattom A; Baker JR
    Hum Vaccin Immunother; 2015; 11(12):2904-12. PubMed ID: 26307915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine.
    Prince GA; Curtis SJ; Yim KC; Porter DD
    J Gen Virol; 2001 Dec; 82(Pt 12):2881-2888. PubMed ID: 11714962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parenteral immunization with live respiratory syncytial virus is blocked in seropositive cotton rats.
    Prince GA; Horswood RL; Camargo E; Suffin SC; Chanock RM
    Infect Immun; 1982 Sep; 37(3):1074-8. PubMed ID: 6752019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.